P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
2020
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
7
Citations
NaN
KQI